Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
Date:11/14/2007

to common stockholders during the first nine months of 2007 was ($0.78), down from a net loss per share of ($0.93) in the first nine months of 2006.

"We believe the Amoxicillin PULSYS NDA review process has progressed very well thus far and we look forward to continuing to work with the FDA throughout the remainder of their review," stated Edward M. Rudnic, Ph.D., president and CEO of MiddleBrook.

OPERATIONAL HIGHLIGHTS

Amoxicillin PULSYS NDA Review -- PDUFA Date January 23, 2008

On May 22, 2007, MiddleBrook's New Drug Application (NDA) for its once- daily Amoxicillin PULSYS product was accepted for filing by the U.S. Food and Drug Administration (FDA). MiddleBrook has worked closely with the FDA throughout the subsequent review process and anticipates a decision on the application on its Prescription Drug User Fee Act (PDUFA) target action date of January 23, 2008.

Amoxicillin is currently not approved for once-daily dosing to treat pharyngitis. If approved for marketing, physicians prescribing Amoxicillin PULSYS would have available the first once-daily product in the aminopenicillin class for the treatment of pharyngitis while utilizing approximately one-half the amount of amoxicillin currently used. About 15 million patients annually seek relief of sore throat symptoms in the United States.

Keflex(R) Capsules (Cephalexin, USP) -- Commercialization Update

During the third quarter, MiddleBrook continued the commercialization of its 750 mg strength Keflex capsules through a targeted and dedicated national contract sales force and MiddleBrook district sales managers. Based on prescription data from IMS Health, total prescriptions filled for Keflex 750 mg capsules in the third quarter of 2007 were 83,767 prescriptions, up from second quarter 2007 total prescriptions of 82,621.

MiddleBrook recently conducted a review of its Keflex sales initiatives and as a result reduced the size of its sales force to approximately 30 c
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... UC San Francisco shows that an "expressive therapy" ... women living with HIV disclose their health status ... safety and quality of their relationships., "Medication alone ... Edward L. Machtinger, MD, director of the Women,s ... our patients are on effective antiretroviral therapy but ...
(Date:7/11/2014)... July 11, 2014 Bedros Keuilian is known ... title he’s earned by founding the fast-selling fitness franchise in ... their businesses. He works with successful boot camp owners on ... on the traits of the most successful boot camp owners ... important qualities. , “I’ve worked with and coached some of ...
(Date:7/11/2014)... When the mercury rises, heat can strain the ... heart, takes on a heavier load in hot weather to ... of the Harvard Men's Health Watch . , For ... than knowing their limits and drinking enough fluids. But what ... more sensitive to the heat," says Dr. Joanne Foody, Director ...
(Date:7/11/2014)... 11, 2014 As reported by Forbes ... Cocaine: Are Genetics To Blame (6/30), Indino Downey has ... and paraphernalia to smoke it with. His father, well-known ... his son inherited from him may have something to ... the news during the 1980s and 1990s for substance ...
(Date:7/11/2014)... Timex, the leader in outdoor and sports performance ... Network, the brand’s new online content portal which will ... and special product offers for consumers. , The ... the Timex IRONMAN watch brand and will serve as ... The hub will reflect the active lifestyle of Timex ...
Breaking Medicine News(10 mins):Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Timex Announces Launch of Timex Performance Network 2
... All PETCO stores nationwide will host a free pet nutrition, ... experts on Saturday, November 14 at 2 p.m. During the 30-minute, ... the nutritional needs of, their dogs ... good pet nutrition, receive an assessment of their individual, ...
... the University of Florida Proton Therapy Institute have formed a ... announcement follows the approval of the first clinical study to ... in children younger than 3 years old. ... receive proton therapy at the UF Proton Therapy Institute in ...
... issue of European Urology , the official journal ... entitled ,Are Infertile Men Less Healthy than Fertile Men? ... Salonia et al. The conclusion is that male factor ... as objectively scored with the hospital-based Charlson Comorbidity Index. ...
... In the construction industry, respiratory disease, often leading to ... major public health concern. Studies led by Deborah ... Construction, have shown that specific types of sanding tools ... these health hazards, yet the industry,s usage of the ...
... The first human embryonic stem cell treatment approved by ... limb function in rats with neck spinal cord injuries ... people with cervical damage. In January, the U.S. Food ... permission to test the UC Irvine treatment in individuals with ...
... ACCRA, Ghana -- The lives of almost 4 million ... saved every year if well-established, affordable health care interventions ... report by the national science academies of seven African ... knowledge to save lives, says the report, which calls ...
Cached Medicine News:Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:European Urology: Male factor infertility associated with comorbidities 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3Health News:UCI embryonic stem cell therapy restores walking ability in rats with neck injuries 2Health News:Using science to save lives of mothers and children in Africa 2Health News:Using science to save lives of mothers and children in Africa 3Health News:Using science to save lives of mothers and children in Africa 4
(Date:7/10/2014)... -- The U.S. Department of Health and Human Services (HHS) ... Case Medical Center Seidman Cancer Center totaling $4.7 million ... care for patients with complex cancer. ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... levels following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus ... tolerability comparable to ... - Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., ... of a 4-week Phase 1,clinical trial to evaluate two oral dose levels ...
... Duration of ... Neutropenia- ... Jan. 7 Maxygen, Inc.,(Nasdaq: MAXY ) today announced positive progress in ... the trial include the following:, -- Patients in the initial 10 ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 2Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 4
... Plate is a semi-rigid system intended ... The Slim-LOC is based on the ... current market technology. The Slim-LOCTM system ... instrumentation. Reduced width (16 mm), low ...
... SC-Acufix anterior cervical plate system is a ... integrated swivel, which provides for consistent, reliable ... bone screw disengagement or backout. This innovative ... locking screw. Simply implant your screws and ...
... a leading provider of telemedicine solutions. ... state-of-the-art technology deliver accurate, reliable and ... professionals and clients in improving outcomes. ... ECG technology to gather patient data, ...
... is a high performance temperature controlled shaker ... shaking speed and incubation time are fully ... parameters are displayed on the LCD in ... below the microplates provide uniform incubation with ...
Medicine Products: